Trials / Completed
CompletedNCT02795182
Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies
A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Assess Safety, Tolerability and Antitumor Activities of the Combination of BGB-3111 With BGB-A317 in Subjects With B-Cell Lymphoid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with BGB-A317 in participants with B-cell lymphoid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanubrutinib | |
| DRUG | Tislelizumab |
Timeline
- Start date
- 2016-06-29
- Primary completion
- 2020-12-18
- Completion
- 2020-12-18
- First posted
- 2016-06-10
- Last updated
- 2022-07-01
- Results posted
- 2022-07-01
Locations
10 sites across 2 countries: Australia, China
Source: ClinicalTrials.gov record NCT02795182. Inclusion in this directory is not an endorsement.